Objective: Centronuclear myopathy (CNM) is a rare congenital myopathy characterized by prominence of central nuclei on muscle biopsy. CNM has been associated with mutations in MTM1, DNM2, and BIN1 but many cases remain genetically unresolved. RYR1 encodes the principal sarcoplasmic reticulum calcium release channel and has been implicated in various congenital myopathies. We investigated whether RYR1 mutations cause CNM. Methods: We sequenced the entire RYR1 coding sequence in 24 patients with a diagnosis of CNM from South Africa (n ¼ 14) and Europe (n ¼ 10) and identified mutations in 17 patients. The most common genotypes featured compound heterozygosity for RYR1 missense mutations and mutations resulting in reduced protein expression, including intronic splice site and frameshift mutations. Results: The high incidence in South African patients (n ¼ 12/14) in conjunction with recurrent RYR1 mutations associated with common haplotypes suggested the presence of founder effects. In addition to central nuclei, prominent histopathological findings included (often multiple) internalized nuclei and type 1 fiber predominance and hypotrophy with relative type 2 hypertrophy. Although cores were not typically seen on oxidative stains, electron microscopy revealed subtle abnormalities in most cases. External ophthalmoplegia, proximal weakness, and bulbar involvement were prominent clinical findings. Interpretation: Our findings expand the range of RYR1-related phenotypes and suggest RYR1 mutations as a common cause of congenital myopathies with central nuclei. Corresponding to recent observations in X-linked CNM, these findings indicate disturbed assembly and/or malfunction of the excitation-contraction machinery as a key mechanism in CNM and related myopathies. ANN NEUROL 2010;68:717-726 
''myotubular myopathy''), 3 whereas dominant dynamin 2 (DNM2) mutations 4, 5, 7 and recessive amphiphysin 2 (BIN1) mutations 6 have been implicated in some families with relatively milder phenotypes. A substantial proportion of cases with variable severity remains currently genetically unresolved. 8 Extraocular muscle involvement is common in all forms of CNM. The MTM1, DNM2, and BIN1 genes all encode proteins with a role in different aspects of membrane trafficking and remodeling. The skeletal muscle ryanodine receptor (RYR1) gene, encoding the principal sarcoplasmic reticulum (SR) calcium release channel with a crucial role in excitation-contraction coupling (ECC), has been implicated in various neuromuscular phenotypes including the malignant hyperthermia susceptibility (MHS) trait, central core disease (CCD) and subgroups of multi-minicore disease (MmD). 9 There is substantial clinical and histopathological overlap between CNM and MmD with ophthalmoplegia, [10] [11] [12] but RYR1 involvement in CNM to date has only been suggested in one isolated patient harboring a single heterozygous missense mutation. 13 The recent observation of disrupted T-tubule assembly in animal models of myotubular myopathy 14, 15 indicates involvement of molecular regulation of ECC as a potentially important pathogenetic mechanism in CNM.
Here we report evidence for frequent RYR1 involvement in a large cohort of patients with a diagnosis of CNM and consistent clinicopathological features.
Patients and Methods

Patients
Patients were selected from a cohort of 24 patients from 23 unrelated, nonconsanguineous families with genetically unresolved CNM. RYR1 mutations were identified in 17 patients, 12 from South Africa and five from the United Kingdom and other European countries. Within the South African group, four patients were of indigenous African ancestry and eight were of ''mixed'' ancestry (referring to people descended from an admixture of Caucasian, Khoisan, Malay, Javanese Sumatran, and black African ancestries). Within the European group, all patients were Caucasian. Detailed histories for each of the 17 patients are provided in Supporting File S1.
Muscle Histology
All patients had muscle biopsies except one boy (Patient 15) The number of fibers with nuclear internalization (ie, nuclei appearing underneath the sarcolemma anywhere within the cytoplasm) and nuclear centralization (ie, nuclei in the geometric center of the fiber) were determined on H&E-stained sections based on a count of at least 200 fibers at a magnification of Â100.
Molecular Genetic Studies
The triplet repeat expansion associated with myotonic dystrophy, histopathologically similar to CNM, was excluded in all patients prior to RYR1 screening. MTM1 mutations were excluded by direct sequencing in the most severely affected male (Patient 13) and all females. In Patients 1, 2, 4, 12, and 13, dynamin 2 (DNM2) mutations were also excluded. In addition, Patient 13 was screened for ACTA1 and TPM3 mutations previously associated with congenital fiber type disproportion (CFTD) 16, 17 because of suggestive histopathological features. The entire coding regions (exons 1-106) of the RYR1 gene including splice sites were screened at the genomic level in all patients and at the RNA level in patients 16 and 17 as previously described. 18 Family members of the probands found to carry RYR1 mutations were investigated for the presence of the mutation identified by direct sequencing where DNA was available.
Haplotyping at the RYR1 Locus
Haplotyping of the unrelated patients carrying any of three recurrent RYR1 mutations identified was carried out using a panel of highly polymorphic microsatellite repeat markers located in and around the RYR1 locus. Those included the intragenic marker RYR1_IVS89 and flanking markers D19S224, D19S896, D19S570, D19S220, 18xAC, D19S897, D19S422, D19S881, 21xGT, D19S47, D19S200 (recombination error rate <1%). The markers were separated by size into two multiplexes and a tagged primer approach was used for polymerase chain reaction (PCR) amplification. Electrophoresis of the products on the ABI3730 was analyzed using the Genemarker software package (supplied by Softgenetics, State College, PA).
RyR1 Protein Quantification
Western blotting of RyR1 protein extracted from patient muscle and densitometric analysis was performed as described previously. 18 
Results
Clinical Findings
The reviewed main clinical findings are in Table 1 and Figure 1 . Eight patients were female and nine were male. Median age at last follow-up was 9 years with a range of 2 years to 23 years. Eleven patients had reduced in utero movements and all except one (Patient 17) presented from birth with hypotonia and weakness. All children but one (Patient 13) attained unsupported sitting but only eight children had attained independent walking at the time of last followup. There was no cognitive involvement. Bulbar involvement leading to feeding difficulties was common; many patients required intermittent nasogastric tube feeding in the neonatal period and three patients subsequently required a gastrostomy. Respiratory tract infections were frequent but in most patients reduced over time. One of the three patients who required intubation and ventilation at birth (Patients 13, 14, 15) subsequently developed a persistent ventilatory requirement necessitating a tracheostomy. Patients had similar phenotypic appearances (Fig 1) with a myopathic facies with inverted V-shaped mouth, external ophthalmoplegia with or without ptosis, hypotonia, proximal weakness, and reduced or absent deep tendon reflexes. The further course in most patients was characterized by slow improvement of muscle strength and, in particular, bulbar and respiratory involvement. No malignant hyperthermia (MH) reactions were recorded but none of the patients had been formally assessed by in vitro contracture testing (IVCT).
Muscle Histology
We reviewed all available muscle biopsies ( Table 2 ; Fig 2) . First muscle biopsies were performed between 2 months and 5 years of age (median age 10.5 months). On the first muscle biopsy, a substantial increase in fibers with nuclear centralization (median 11%; range 3-30%) and with nuclear internalization (median 10.5%; range 3-34%), often multiple, was present in all patients (Fig 2A) . Fibers containing central nuclei were often very small. Mild to moderate increases in fat and/or connective tissues were seen in most cases. In one patient (Patient 17) necklace fibers 19 were identified as an additional finding. Type 1 predominance (Fig 2B,C) was present in the first muscle biopsy in all patients except Patients 9 and 10. In addition, type 2 hypertrophy and fiber type disproportion with type 2 fibers at least 25% larger than type 1 fibers (Fig 3A-C) was present in 12 biopsies. With stains for oxidative enzymes central accumulation of stain ( Fig 2C) was consistent but peripheral halos commonly seen in X-linked myotubular myopathy were only seen in three patients (Patients 5, 14, 17) . Radial strands were not observed. None of our patients had corelike structures on the first muscle biopsy but two had a ''moth-eaten'' appearance with oxidative enzyme stains (Patients 2, 6). Central or minicores developed with age in two out of three patients who had follow-up biopsies later in life (Patients 16, 17), but were not a prominent feature. In addition, Z-line streaming was observed on 14 biopsies where electron microscopy was performed and on five of these additional core-like structures were seen (Fig 2D) . One patient had unevenness of stain with ATPase reactions on follow-up biopsy at 3.5 years but this was not observed on corresponding oxidative stains (Fig 3A-C) .
Molecular Genetic Analysis, RYR1 Haplotyping, and RyR1 Protein Quantification
The main genetic findings (Supporting File S2) were characterized by compound heterozygosity for RYR1 nonsense and missense mutations. Within the South African CNM population, three recurrent RYR1 mutations could be identified: 1) c.5726_5727delAG, p.Glu1909GlyfsX39 (exon 35) always associated with c.9242T>C p.Met3081Thr (exon 63) (n ¼ 2); 2) c.8342_8343delTA, p.Ile2781ArgfsX49 (exon 53) always associated with c.11941C>T, p.His3981Tyr (exon 87) (n ¼ 3); and 3) c.14524G>A, p.Val4842Met (exon 101) always in conjunction with c.10348-6C>G (intron 68) (n ¼ 11). We were able to propose common haplotypes associated with each of the three recurrent RYR1 variants, supporting the presence of founder effects in this cohort (Fig 4) . parent was identified. The molecular basis for the marked phenotypical variability in these families is uncertain. In addition to a number of RYR1 mutations expected to result in premature stop codons, the intronic variant c.3381þ1 G>A identified in Patient 7 is predicted to introduce a new splice donor site, whereas the c.8067G>T substitution found in Patient 13 is predicted to abolish the splice donor site of exon 50. Corresponding to the presence of nonsense mutations, we could demonstrate reduction of the RyR1 protein in Patients 2-6 (Fig 5) . However, protein reduction in excess of 50% in some patients could not be accounted for by the presence of a presumably randomly expressed heterozygous nonsense mutation alone and is likely to reflect an additional and variable effect of the allelic intronic c.10348-6C>G substitution identified in 11 patients. Previous work 11 suggested that this variation results in the production of an aberrant transcript that includes intron 68 and introduces a premature stop codon (p.His3449ins33fsX54), but that the penetrance of this mutation is incomplete, There is a predominance of hypotrophic type 1 fibers (that appear dark with acidic preincubation but light at pH 9.4) and few hypertrophic type 2 fibers (that appear light with acidic preincubation but dark at pH 9.4). Fiber size disproportion between type 1 fibers and type 2 fibers is in excess of 25%. There is unevenness of stain in a few fibers. Scale bar 5 50 lm. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary. com.] resulting in the expression of both spliced and unspliced transcripts. We therefore hypothesize that the c.10348-6C>G; p.His3449ins33fsX54/c.14524G>A; p.V4842M genotype determines the phenotype by two interrelated mechanisms, first by reducing the amount of the RyR1 protein, but also the effect of the c.9242T>C; p.V4842M mutant on the residual protein.
Discussion
Our findings identify RYR1 mutations as a common cause of congenital myopathies with central nuclei and further expand the wide phenotypical spectrum associated with mutations in this gene.
Investigation of the RYR1 gene in our cohort had been prompted by our previous finding of a single heterozygous RYR1 mutation in an isolated case with a diagnosis of CNM 13 and the remarkable clinical overlap between genetically unresolved cases with a diagnosis of CNM and RYR1-related core myopathies with external ophthalmoplegia. [10] [11] [12] In terms of overall severity, our cohort falls between the most severe form of CNM due to mutations in the MTM1 gene (''myotubular myopathy, XLMTM'') and mild dominant cases associated with mutations in the DNM2 gene. Although profoundly weak and hypotonic at birth, most patients improved substantially over time. However, one particularly severely affected male (Patient 13) required permanent ventilation and was initially thought to have XLMTM, suggesting that RYR1 mutations ought to be considered in males with similar features once MTM1 mutations have been excluded. Cardiac involvement was not present in any of our patients. Although none of our patients had an overt MH reaction, in the absence of IVCT proof to the contrary we consider all patients with RYR1-related CNM at potential MH risk. It is of note that MH reactions have been reported previously in a genetically unresolved CNM case, suggesting possible RYR1 involvement. 21 Although considered sufficiently frequent to constitute a diagnosis of CNM, the total number of central nuclei was probably lower than in other genetic forms of CNM, and fibers with internal nuclei, often multiple, were a consistent additional finding. The exclusive presence of centralized nuclei as, for example, seen in the most severely affected males with X-linked myotubular myopathy was not a feature in our cohort; this has previously been reported in DNM2-related CNM 6 but also more mildly affected males and manifesting carriers with XLMTM. 19 Most patients had marked increases in fat and connective tissue but other more overtly dystrophic features such as necrosis and regeneration were conspicuously absent. Increases in fat and connective tissue have also been described in other RYR1-related myopathies 22 and DNM2-related CNM 6 but are not a feature in severely affected males with XLMTM. However, this may reflect an age-dependent effect, because similar findings have been documented in older manifesting females. 23, 24 ''Necklace'' fibers, recently reported in more mildly affected males and manifesting carriers with XLMTM, 19 were only seen in one patient. Type 1 predominance and hypotrophy with relative type 2 hypertrophy were almost invariable and resembled pathological features seen in congenital fiber type disproportion (CFTD). 25 Common oxidative enzyme abnormalities comprised central accumulation of stain, but the peripheral halos of reduced oxidative activity characteristic of XLMTM was only seen infrequently, whereas the radial strands characteristic of older patients harboring DNM2 mutations 4 were generally absent. Despite the marked clinical overlap with RYR1-related core myopathies, the presence of central and internalized nuclei was the main histopathological feature and cores on oxidative enzyme stains were generally not observed at presentation. However, as many patients showed subtle ultrastructural abnormalities, and some patients developed cores on follow-up biopsy, as previously suggested those probably develop with age and indicate RYR1 involvement. 26 Although the diagnosis of ''centronuclear myopathy'' was unequivocally established by an experienced pathologist in each case at presentation, the common occurrence of central and often multiple internalized nuclei as well as evolution of cores over time raises the difficult question of boundaries between specific congenital myopathies and resulting problems of nomenclature. Also in line with recent work on CNM as a ''widening concept,'' 27 we propose the term ''congenital myopathies with central nuclei'' as a more accurate description of the entity described in this study, emphasizing central nuclei as the defining histopathological feature, while implicitly acknowledging the presence of additional findings such as multiple and internalized nuclei. Interestingly, it is of note that some CNM patients described before the genetic resolution of the condition (including, notably, the original patient reported by Spiro et al 3 ) shared more clinicopathological features with the entity described in this study than with other genetic forms of CNM, indicating that they may have had a similar genetic background.
The majority of our patients had a genetic background characterized by compound heterozygosity for one mutation expected to result in a reduced RyR1 protein and an allelic heterozygous RYR1 missense mutations, as previously reported in other RYR1-related myopathies. 11, 28, 29 Although most cases were compatible with recessive inheritance, three patients with identical clinical features had only one single heterozygous RYR1 mutation inherited from an asymptomatic parent. The significance of these findings is uncertain, but possible explanations include an allelic large RYR1 intragenic deletion 30 not identifiable with the applied techniques, other copy number variations, promoter mutations or digeny for the RYR1 mutation identified, and a mutation in a functionally related gene. In contrast to CCD due to heterozygous dominant RYR1, no mutational hotspots were identified. Unexpectedly, we found three recurrent RYR1 haplotypes in the South African cohort, suggesting the presence of founder effects in this population, in keeping with a substantial number of earlier reports of CNM 31 and other RYR1-related phenotypes in South Africa. [32] [33] [34] [35] Probably due to this founder effect, congenital myopathy with central nuclei appears to be the most common form of congenital myopathy at the Western Cape, at variance Protein extracted from muscle biopsies shows a significant reduction of RyR1 expression (565 kDa) compared to the control sample. Desmin immunoreactivity was used as a muscle-specific internal control. Semiquantification using densitometric analyses showed a reduction of RyR1 protein levels in patients from 16 to 60% of a normal control.
with its relatively low incidence in other populations. Recurrent mutations in the South African population have been reported for other conditions such as cystic fibrosis 36 and galactosemia. 37 Our findings raise the question of molecular mechanisms common to RYR1-related congenital myopathy with central nuclei and other forms of CNM with distinct genetic backgrounds. The three major genes previously implicated in different forms of CNM-MTM1, BIN1, and DNM2-are intricately linked to different aspects of membrane trafficking and endocytosis and a functional link to RYR1, encoding the principal sarcoplasmic reticulum calcium release channel (RyR1) with a crucial role in excitation-contraction coupling (ECC), is not immediately apparent. However, recent findings indicate a role of the myotubularin-amphiphysindynamin pathway in the assembly of T-tubules and other structural components of the ECC machinery, [38] [39] [40] [41] [42] as well as the possibility of phosphoinositide-mediated mechanisms of ion channel regulation, 43, 44 suggesting potential molecular links. In addition, specific defects of T-tubule and Ryr1 receptor assembly in particular have been documented in two animal models of myotubular myopathy. 14, 15 Regardless of mechanism, however, our study identifies RYR1 as a significant contributor to the pathogenesis of congenital myopathies with central nuclei. In addition, supported by emerging data demonstrating a direct link between other CNM gene products and the regulation of T-tubule/SR structure and function, our findings suggest disturbance of the excitationcontraction coupling machinery as a principal molecular mechanism in various forms of congenital myopathies with central nuclei or, indeed, the congenital myopathies as a group.
